Shots:The US FDA has granted ODD to CAL101 for the treatment of idiopathic pulmonary fibrosis (IPF)CAL101 (IV, QM for 7mos.) is being investigated in a P-II (AURORA) trial against PBO in 150 IPF pts, with enrolment open in the sites across US, UK, EU, Turkey, & South Korea, evaluating lung function per forced vital…
